<qa>  What is the name of the study that fulvestrant and ZACTIMA are combined withThe purpose of this study is to evaluate whether the combination of fulvestrant and ZACTIMA, versus fulvestrant plus placebo, results in a significant decrease in the bone marker, urinary N-Telopeptide NTx in postmenopausal women with bone only, or bone predominant, hormone receptor-positive metastatic breast cancer. A significant decrease will be defined as a 30 reduction in urinary NTx level from baseline. 